Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease

Yuri Shelygin, Zoran Krivokapic, S. A. Frolov, I. V. Kostarev, V. L. Astashov, S. V. Vasiliev, A. V. Lakhin, G. V. Rodoman, A. O. Soloviev, Y. M. Stoyko, A. G. Khitaryan, I. A. Nechay

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

To compare the clinical acceptability of micronized purified flavonoid fraction (MPFF) 1000mg with MPFF 500mg tablets, administered at the same daily dose in patients suffering noncomplicated acute hemorrhoids. Background: MPFF is an established treatment for hemorrhoidal disease. Methods: This was a double-blind, multi-center, randomized study. Patients took either MPFF 1000mgor 500mg tablets for 7 days (daily dose; 3 g over 4 days followed by 2 g over 3 days). Adverse events were recorded in a patient diary. On day 7, anal pain and bleeding were assessed (visual analog scale [VAS] and Dimitroulopoulos scale, respectively). Results: Patients (162) were randomized to MPFF 1000mg (79) and MPFF 500mg (83). No serious adverse events (AEs) occurred; 10 emergent AEs were considered treatment-related (6 for MPFF 1000mg and 4 for 500 mg). Both regimens were associated with significant reduction in anal pain (VAS); 2.37 cm MPFF 1000mg (P
Original languageEnglish
JournalCurrent Medical Research and Opinion
Volume32
Issue number11
DOIs
StatePublished - 2016
Externally publishedYes

Keywords

  • Acceptability
  • Anal pain
  • Bleeding
  • Hemorrhoidal disease
  • MPFF

Fingerprint

Dive into the research topics of 'Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease'. Together they form a unique fingerprint.

Cite this